Ortho-Clinical Diagnostics announced the launch of NephroCheck Test System to help identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of assessment. The NephroCheck Test System is indicated for use with clinical evaluation in patients aged ≥21 years who have or have had (within past 24 hours) acute cardiovascular and/or respiratory compromise, and are ICU patients.

The test result, called the AKIRisk Score, can identify patients with AKI and those without AKI within 20 minutes. Those with a positive AKIRisk Score (>0.3) have a 25–33% chance of developing moderate or severe AKI within 12 hours of assessment. In clinical studies, NephroCheck Test was able to detect the majority of patients that developed moderate to severe AKI within 12 hours of the post-test.

RELATED: First-of-Kind Kidney Injury Risk Test Gets FDA Nod

NephroCheck Test System works by measuring 2 urinary biomarkers, tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP-7), through the ASTUTE140 Meter. The two biomarkers are resumed to be involved in the G1 cell cycle arrest in the earliest phase of injury.

The NephroCheck Test System contains the ASTUTE140 Meter, NephroCheck Test Kit, NephroCheck Liquid Controls Kit, and the NephroCheck Calibration Verification Kit.

For more information call or visit AstuteMedical.com.